Search

Your search keyword '"Carolien Wylock"' showing total 2 results
Start Over Author "Carolien Wylock" Topic hiv-1
2 results on '"Carolien Wylock"'

1. Corrigendum to 'A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption' [Clin. Immunol. 142 (2012) 252-268]

Author

Walter E.P. Beyer, Joeri L. Aerts, Albert D. M. E. Osterhaus, Patrick Lacor, Marchina E. van der Ende, Mariska L. Reedijk, Kris Thielemans, Carlo Heirman, Rob A. Gruters, Brenda De Keersmaecker, Annelies De Bel, Judith Vandeloo, Anna L. de Goede, Esther J. Verschuren, Jeanette Koetsveld, Frank H. M. Pistoor, Paul H. C. Eilers, Sabine Allard, Iman Padmos, Jurgen Corthals, Carel A. van Baalen, Carolien Wylock, Clinical sciences, Internal Medicine, Basic (bio-) Medical Sciences, Laboratory of Molecullar and Cellular Therapy, Supporting clinical sciences, Immunomodulation in Chronic Inflammatory Diseases, Medical Oncology, UZB Other, Physiology, and Microbiology and Infection Control

Subjects
business.industry, Treatment interruption, medicine.medical_treatment, Immunology, Human immunodeficiency virus (HIV), HIV-1, Medicine, Immunology and Allergy, Immunotherapy, business, medicine.disease_cause, Virology
Abstract

Corrigendum to ‘A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption’ [Clin. Immunol. 142 (2012) 252–268] Sabine D. Allard⁎, Brenda De Keersmaecker, Anna L. de Goede, Esther J. Verschuren, Jeanette Koetsveld , Mariska L. Reedijk , Carolien Wylock, Annelies V. De Bel , Judith Vandeloo, Frank Pistoor , Carlo Heirman, Walter E.P. Beyer , Paul H.C. Eilers , Jurgen Corthals , Iman Padmos, Kris Thielemans, Albert D.M.E. Osterhaus , Patrick Lacor, Marchina E. van der Ende, Joeri L. Aerts , Carel A. van Baalen, Rob A. Gruters c,2

Published
2014

2. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption

Author

Mariska L. Reedijk, Kris Thielemans, Sabine Allard, Walter E.P. Beyer, Paul H. C. Eilers, Rob A. Gruters, Marchina E. van der Ende, Jurgen Corthals, Carlo Heirman, Patrick Lacor, Joeri L. Aerts, Judith Vandeloo, Iman Padmos, Brenda De Keersmaecker, Albert D. M. E. Osterhaus, Jeanette Koetsveld, Anna L. de Goede, Frank H. M. Pistoor, Esther J. Verschuren, Annelies De Bel, Carel A. van Baalen, Carolien Wylock, Physiology, Immunology and Microbiology, Laboratory of Molecullar and Cellular Therapy, Internal Medicine Specializations, Microbiology and Infection Control, Pharmacy, Virology, Epidemiology, and Internal Medicine

Subjects
Cart, Adult, Male, medicine.medical_treatment, Immunology, HIV Infections, Peripheral blood mononuclear cell, Immune system, SDG 3 - Good Health and Well-being, Immunology and Allergy, Medicine, Humans, nef Gene Products, Human Immunodeficiency Virus, dendritic cells, Adverse effect, Cells, Cultured, Aged, AIDS Vaccines, Nef, business.industry, Immunotherapy, Middle Aged, Virology, Clinical trial, Vaccination, Gene Products, rev, Gene Products, tat, HIV-1, Immunization, immunotherapy, Tat, business, CD8, Rev
Abstract

In a phase I/IIa clinical trial, 17 HIV-1 infected patients, stable on cART, received 4 vaccinations with autologous dendritic cells etectroporated with mRNA encoding Tat, Rev and Nef, after which cART was interrupted. Vaccination was safe and feasible. During the analytical treatment interruption (All), no serious adverse events were observed. Ninety-six weeks following ATI, 6/17 patients remained off therapy. Although induced and/or enhanced CD4(+) and CD8(+) T-cell responses specific for the immunogens were observed in most of the patients, we found no correlation with the number of weeks off cART. Moreover, CD4(+) T-cell counts, plasma viral load and the time remaining off cART following ATI did not differ from historical control data. To conclude, the vaccine was safe, well tolerated and resulted in vaccine-specific immune responses. Since no correlation with clinical parameters could be found, these results warrant further research in order to optimize the efficacy of vaccine-induced T-cell responses. (C) 2011 Elsevier Inc. All rights reserved.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results